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Abstract
Background: The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can
be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation
by promoter methylation; or miRNA-mediated silencing. This study aimed to establish a correlation among
the BRCA1-related molecular parameters, tumor characteristics and clinical follow-up of patients to find new
prognostic factors.
Methods: BRCA1 protein and mRNA expression was quantified in situ in the TNBCs of 69 patients. BRCA1
promoter methylation status was checked, as well as cytokeratin 5/6 expression. Maintenance of expressed
BRCA1 protein interaction with BARD1 was quantified, as a marker of BRCA1 functionality, and the tumor
expression profiles of 27 microRNAs were determined.
Results: miR-548c-5p was emphasized as a new independent prognostic factor in TNBC. A combination of
the tumoral expression of miR-548c and three other known prognostic parameters (tumor size, lymph node
invasion and CK 5/6 expression status) allowed for relapse prediction by logistic regression with an area
under the curve (AUC) = 0.96.
BRCA1 mRNA and protein in situ expression, as well as the amount of BRCA1 ligated to BARD1 in the tumor,
lacked any associations with patient outcomes, likely due to high intratumoral heterogeneity, and thus could
not be used for clinical purposes.
Conclusions: In situ BRCA1-related expression parameters could be used for clinical purposes at the time of
diagnosis. In contrast, miR-548c-5p showed a promising potential as a prognostic factor in TNBC.
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Background
Breast cancer susceptibility gene 1 (BRCA1) was the first
tumor suppressor gene identified in breast and ovarian
cancer. Located on chromosome 17 (17q21), it encodes
a multifunctional protein that is involved in several cellu-
lar processes such as DNA repair and cell cycle control.
BRCA1 is involved in large protein complexes and its
interaction with other proteins, as BARD1, is required for
its function.
BRCA1 seems to be associated with the triple negative
breast cancer (TNBC) subtype because the histological
features and clinical outcomes of TNBC sporadic tumors
can be very similar to those found in the tumors of
BRCA1 germline mutated patients. The traits that some
sporadic cancers share with those occurring in BRCA1
mutation carriers were described and called ‘BRCAness’
by Turner et al. [1]. In particular, these cancers present
a high rate of chromosomal alterations reflecting the
absence of the BRCA1 DNA repair function.
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TNBC has a poor prognosis and no targeted therapy is
currently available. Because these cancers are heteroge-
neous in terms of therapeutic response, new therapeutic
solutions are being sought. In this context, recent clinical
data have shown that BRCA1-associated breast cancers
appeared to be more sensitive to platinum agents in
neoadjuvant chemotherapy than non-hereditary tumors
[2–4]. In contrast, a phase II clinical trial found that poly
(ADP-ribose) polymerase (PARP) inhibitors also showed
promising activity in BRCA1-mutated breast cancer al-
though there were no response in patients with TNBC
regardless of BRCA1/2 mutation status [5], and phase
III trials are ongoing in BRCA1/2-mutated BC and
TNBC [6].
However, it is also becoming clear that germline BRCA1/
2 mutations are neither necessary nor sufficient for patients
to derive benefit from these agents [6]. This variability of
response can be explained by different BRCA1 protein ex-
pression statuses inside the tumor, as several cases can be
met : (i) germline BRCA1 is mutated in one allele, and the
second is lost; thus, BRCA1 tumoral expression is missing
[7, 8] (ii) germline BRCA1 is mutated in one allele, and
the second is still active, so tumoral BRCA1 expression
is normal; (iii) germline BRCA1 is mutated, but reversal
somatic mutation occurs, and BRCA1 tumoral expres-
sion is restored, leading to PARP inhibitor treatment
resistance [9, 10]; (iv) germline BRCA1 is normal, but
tumoral expression is lost by promoter hypermethylation
[11]; and (v) germline BRCA1 is normal, but tumoral ex-
pression is lost by post-transcriptional regulation, such as
by miRNAs [12]. One could expect a greater likelihood of
response for patients treated with platinum compounds or
PARP inhibitors only if BRCA1 protein tumoral expres-
sion were lost. As a consequence, better characterization
of BRCA1 expression status in TNBC would provide im-
portant knowledge to improve chemotherapy choices.
MicroRNAs are small non-coding RNAs that bind to
the 3’ untranslated (3’UTR) region of target messenger
RNAs (mRNAs), and they are known to regulate gene
expression. They are deregulated in breast cancers:
some of them are known to be oncogenic, and others are
known as tumor suppressors. MiRNAs participate in a
variety of biological processes, such as the immune re-
sponse, as well as proliferation and metastasis, which
are hallmarks of cancer [13, 14]. Many studies have im-
plicated miRNAs in chemotherapy resistance, such as
to cisplatin [15], and some of them have been used as
prognostic biomarkers [16–18]. Moreover, some miRNAs
could target BRCA1 mRNA expression, and, at the same
time, their expression was affected by BRCA1 protein
[12, 19–21].
Currently, the number of conventional breast cancer
prognostic factors is limited (tumor size, histology and
grade, hormone receptors status, lymph nodes invasion,
proliferative index [Ki67], and tumor-infiltrating lympho-
cytes, as well as the age of the patient), and their use does
not allow for accurate prediction of treatment resistance
or relapse in TNBC. Defining new molecular prognostic
factors to refine TNBC classification would be useful in
facilitating a more adapted chemotherapy choice.
In this context, we quantified molecular parameters
focusing on the BRCA1 gene expression regulation and
function (BRCA1 promoter methylation, BRCA1 in situ
mRNA expression, BRCA1 in situ protein expression and
BRCA1 in situ interaction with BARD1) in 69 TNBC
tumors from patients. The expression of 27 tumoral
miRNAs was also measured. Those molecular parameters
were associated with progression-free survival in uni- and
multivariate statistical analyses to determine new prognos-
tic factors.
Methods
More detailed protocols are available in Additional file 1.
Ethical statement
Ethical approval was obtained from the local institutional
ethics board (Comité d’éthique hospitalo-facultaire univer-
sitaire de Liège) in compliance with the Helsinki declar-
ation. All of the patients were recruited on the basis of an
opt-out methodology.
Patient and sample collection and study design
This retrospective study was performed on 69 formalin-
fixed paraffin embedded (FFPE) tumoral samples obtained
from the Liege University Biobank. The tissues stored in
this biobank are available on condition that the study has
received the consent of a local or external ethical board.
The tumors were collected from 1999 to 2010, with a
median follow-up of 11 years. The essential elements of
“Reporting recommendations for tumor marker prog-
nostic studies (REMARK)” were followed [22].
The clinicopathological characteristics of the patients
are summarized in Table 1.
A summary of the experimental design and the number
of samples included in each type of analysis are shown in
Fig. 1.
DNA and RNA extraction
DNA and RNA extraction was performed using an All Prep
DNA/RNA FFPE extraction kit from Qiagen (Belgium)
according to manufacturer protocol. Multiplex PCR for
increasing the size amplicons of a house keeping gene
was performed to assess the nucleic acid quality, as de-
scribed by van Beers et al. [23].
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BRCA1 promoter methylation
The methylation status of BRCA1 promoter was assessed
by methylation-specific PCR (MSP), as described by
Esteller et al. [24].
BRCA1 mRNA expression
The mRNA expression was assessed by in situ hybridization
using RNAscope technology (ACD) (Bioke, the Netherlands)
for FFPE samples, as described in our previous work [25].
Signal quantification was performed using the Cytomine ap-
plication (http://www.cytomine.be/, Marée et al. 2013) [26].
BRCA1 mRNA expression was expressed as a percentage of
the median expression value measured in the whole group.
BRCA1 protein expression and interaction with BARD1
BRCA1 expression level and interaction with BARD1 were
assessed by proximity ligation assay (Duolink in situ detec-
tion reagents—Sigma, Belgium), as described in [25] and
in Additional file 1. Two antibodies raised against BRCA1
were used for the whole-length protein detection assays,
and one antibody against BRCA1 and a second against
BARD1 were used for interaction assays. The amount of
BRCA1 protein and the amount of BRCA1-ligated to
BARD1 were expressed as a percentage of their respective
median expression values measured in the whole group.
Tumoral miRNA expression assessment
A total of 27 miRNAs were quantified by RT-qPCR in
tumors using miRCURY LNA™ Universal RT microRNA
PCR assays from Exiqon (Denmark), according to the
manufacturer’s instructions. Those miRNAs were chosen
because: (i) their expression was reported in the literature
to be related to the survival of breast cancer patients; (ii)
they are known to be expressed in lymphoid cells and to
reflect the lymphoid invasion of the tumor; or (iii) they
were emphasized in our previous work (unpublished re-
sults). The miRNAs quantified, their sequences and the
reasons for choosing them are listed in Additional file 2.
Quantification was realized using standard curve method.
Normalization was performed using the geometric mean of
five endogenous control genes. The miRNA amounts were
expressed in percentages relative to the median expression
value of the whole group.
Statistical analysis
Statistical analysis were performed with SPSS software
(version 20.0: IBM SPSS), and checked with R software
(version 3.1.0). Some of the graphs were drawn with Graph-
Pad Prism software, version 5.
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Fig. 1 Schematic representation of the study
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Results
Quantification of in situ BRCA1 mRNA and protein
expression
To assess the BRCA1 expression status inside the tumors,
the amount of BRCA1 protein was first measured by prox-
imity ligation assays (PLAs) in fixed TNBC tissues. Repre-
sentative in situ BRCA1 protein expression is shown in
Fig. 2a. As a second step, the BRCA1 mRNA expression
level was visualized and quantified in the same tissues, by
in situ hybridization (Fig. 2b).
The most striking observation was that the staining
for both mRNA and protein is heterogeneous across the
tumor: some areas strongly expressed BRCA1 and others
only faintly, as illustrated in the two magnified subzones.
The staining was restricted to epithelial cells.
Univariate analyses showed that neither BRCA1 protein
nor mRNA expression was associated with progression-
free survival (PFS) (Fig. 2c). The entire dataset and all of
the univariate analyses performed in this study are avail-
able in Additional files 3 and 4.
Quantification of in situ BRCA1-BARD1 interaction
Proximity ligation assays were performed to quantify
the in situ interaction of BRCA1 with its interacting
protein, BARD1. Statistical analyses revealed that the
percentage of BARD1-ligated BRCA1 was correlated with
BRCA1 protein and mRNA expression. However, no as-
sociation was observed with PFS in univariate analysis
(Fig. 2c).
Fig. 2 In situ BRCA1 expression in TNBC tumors. a Proximity ligation assay showing a representative BRCA1 protein expression across the tumor.
Two different subzones were magnified to illustrate high and faint expression. b In situ hybridization assay showing BRCA1 mRNA expression
across the same tumor and subzones used for protein detection. In both cases, high heterogeneity of the localization of expression is observed.
c. Cox univariate regression and correlation analyses of BRCA1 expression relative to patient clinicopathological features. No relationship of BRCA1
expression with patient outcome was observed
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BRCA1 promoter methylation and survival
The methylation status of BRCA1 promoter was checked
by methylation-specific PCR in tumoral DNA extracted
from fixed TNBC tissues. Twenty-seven of the 69 patients
(39 %) carried a methylated BRCA1 promoter, but we did
not observe any associations of BRCA1 promoter methyla-
tion with patient outcomes or with BRCA1 mRNA expres-
sion (Additional file 5). However, an expected negative
correlation was observed between methylation and protein
expression in the infiltrating ductal carcinoma sub-group.
Micro-RNA profiling in tumors
The tumoral expression of 27 miRNAs was quantified
by RT-qPCR in RNA extracted from fixed TNBC tissues.
Spearman’s correlations were calculated of the studied
miRNAs and BRCA1 mRNA with protein expression,
BARD1-BRCA1 interaction, and promoter methylation
status. The entire dataset is presented in Additional file 3.
BRCA1 protein expression was positively correlated with
miR-143-3p (p = 0.033), miR-205-5p (p = 0.030), miR-21-5p
(p = 0.017), and miR-142-5p (p = 0.011). In contrast, no cor-
relation was noted with BRCA1 mRNA. Promoter methyla-
tion was negatively correlated with miR-21-5p (p = 0.024)
and positively correlated with miR-197-3p (p = 0.019).
Univariate Cox regression analyses were also conducted
to emphasize the associations of miRNA expression with
patient outcomes (Table 2 and Additional file 4). High ex-
pression of miR-210, miR-205-5p, miR-484, and miR-93-5p
were significantly associated with an increased risk of
relapse, and miR-342-3p, reflecting lymphoid cell infiltra-
tion [27], was associated with a good prognosis (Table 2).
Prediction of relapse using multivariate analysis
Univariate Cox proportional hazards regression analyses
were first conducted to evaluate the association of clini-
copathological factors with patient PFS (Additional file
4). Node invasion, cytokeratin five and six expression,
bloom = 3 and the size of the tumor are associated with
relapse.
In multivariate Cox analysis, three parameters remained
as independent prognostic factors: node invasion status,
tumor size, and the expression of miR-548c-5p (node inva-
sion: Exp(B): 16.576; CI: 2.876–95.538; p-val: 0.002—tumor
size: Exp(B): 1.065; CI: 1.027–1.105; p-val: 0.001—miR-
548c-5p: Exp(B): 0.993; CI: 0.987–0.999; p-val: 0.023).
An outcome prediction model was built by binomial
logistic regression. The best prediction model used node
invasion, the size of the tumor, cytokeratin 5/6 expression
status and miR-548c-5p. Because the first three variables
were already known to be prognostic factors, we com-
pared the performances of two models, containing or not
containing the miR-548c-5p expression variable, to evalu-
ate the improvement of the prediction of relapse by this
miRNA (Fig. 3). The addition of miR-548c-5p statisti-
cally improved the model (Chi-square p-val = 0.00144). A
ROC curve corresponding to the probability of relapse for
each patient, calculated by these two models, is shown in
Fig. 3a. The use of miR-548c-5p expression allowed for the
improvement of the AUC from 0.854 (CI:0.713 to 0.996)
Table 2 Univariate Cox analysis
Variable N total N relapse Global pval B Sign Exp(B) 95% CI
miR-210 49 20 0.00 .004 .000 1.004 1.002 1.007
miR-205-5p 49 20 0.00 .003 .002 1.003 1.001 1.005
Node 53 21 0.00 −1.344 .003 .261 .108 .630
miR-484 49 20 0.01 .004 .015 1.004 1.001 1.008
CK 61 20 0.02 1.106 .024 3.023 1.159 7.881
miR-93-5p 49 20 0.02 .003 .019 1.003 1.001 1.006
Bloom = 3 65 23 0.03 1.963 .055 7.117 .957 52.955
miR-342-3p 49 20 0.04 −.005 .049 .995 .990 1.000
Size 57 18 0.05 .016 .055 1.016 1.000 1.032
Age 68 24 0.07 .025 .070 1.025 .998 1.053
Bloom = 1 65 23 0.08 −3.195 .262 .041 .000 10.892
miR-146a 49 20 0.09 −.004 .093 .996 .992 1.001
miR-143-3p 49 20 0.11 .003 .116 1.003 .999 1.007
miR-155-5p 49 20 0.11 −.003 .123 .997 .993 1.001
miR-150-5p 49 20 0.12 −.004 .151 .996 .991 1.001
miR-142-3p 49 20 0.18 −.003 .195 .997 .993 1.002
miR-548c-5p 49 20 0.19 −.001 .196 .999 .997 1.001
miR-374a-5p 49 20 0.20 −.005 .200 .995 .988 1.003
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to 0.958 (CI:0.883–1.000)(Table 3). Thresholds for both
models were chosen to fix relapse detection sensitivity at
90 %. Using these thresholds, the patients were assigned by
each model into two risk groups: low or high risk of relapse.
Kaplan-Meier PFS curves were generated using these effect
groups for both models, and they are shown in Fig. 3b.
Classification performances of the compared models are
presented in Fig. 3c, and metrics are shown in Fig. 3d (with
miR-548c) and 3e (without miR-548c) and in Table 3.
Interestingly, a comparison of two groups of patients
presenting with extreme relapse probabilities (<10 %
and >90 %), calculated by the predicting model including
miR-548c, showed that patients with poor prognoses
present higher expression of miR-503-5p, miR-210 and
BRCA1 mRNA.
In contrast, the addition of BRCA1-related parameters
(mRNA, protein and BARD1 ligated to BRCA1) to the
same three conventional prognostic factors (node invasion,
Fig. 3 miR-548c-5p as factor in relapse prediction model. Performances of two models are compared to measure the improvement of relapse
prediction by the inclusion of the miR-548c-5p as a 4th variable, with the first three variables being node invasion, CK5/6 expression, and tumor
size. a Comparison of ROC curves computed with the relapse probability calculated by the model including miR-548c-5p (solid line) and without
miR-548c-5p (dash line). b Patients were classified in two groups: high and low risk of relapse, according to the threshold needed to obtain 90 %
sensitivity in relapse prediction. Comparison of Kaplan-Meier curves computed with the patient group affectation calculated by the model including
miR-548c-5p (solid line) and without miR-548c-5p (dash line). c Classification performances of the two models at thresholds fixed to obtain
90 % sensitivity in relapse detection. d Coefficient and odds ratio of the model including miR-548c-5p and e without miR-548c-5p. f Comparative
expression levels of miR-210, miR-503-5p and BRCA1 mRNA in the patients with <10 % probability of relapse (remission) and >90 % probability of
relapse (relapse). These probabilities were calculated by the prediction model including miR-548c-5p
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tumor size and CK5/6 expression) did not improve the
model performances (Fig. 4 and Table 3).
Discussion
An accurate technique to determine BRCA1 tumoral
expression status in TNBC would allow for informed
decision and choosing platinum derivatives or PARP in-
hibitor treatments, because hypersensitivity to these
agents has been described in cases of loss of BRCA1 ex-
pression [3, 5]. Thus, we developed alternative techniques
to evaluate, in tumors, the expression status of BRCA1 at
three different levels: mRNA, protein, and maintenance of
BRCA1 interaction with BARD1. This multiple approach
presented the advantage of incorporating different types of
information, allowing for cross-control, and offering the
possibility of combining the data. Several BRCA1 studies
have described mRNA expression using RT-qPCR or pro-
tein expression by immunohistochemistry, but studies de-
scribing both mRNA and protein expressions has been
very rare [28], despite BRCA1 expression being known to
be subjected to multiple regulations [19]. The commer-
cially available antibodies directed against BRCA1 lack
the specificity required to identify the BRCA1 protein
for clinical purpose because no immunohistochemical
Fig. 4 BRCA1 expression as factor in relapse prediction models. Performances of two models are compared: the first model (solid line) includes
BRCA1 expression parameters mRNA, protein expression and BARD1-ligated BRCA1, in addition to the three previously used conventional prognostic
factors for breast cancer: tumor size, node invasion, CK5/6 expression. The second model (dash line) is composed of the three conventional prognostic
factors only. a Comparison of ROC curves computed with the relapse probability calculated by the BRCA1-related model (solid line) and the
three conventional prognostic factor model (dash line). b Patients were classified in two groups: good or bad prognosis, according to the
threshold needed to obtain 90 % sensitivity in relapse detection. Comparison of Kaplan-Meier curves computed with the patient group affectation
calculated by the two models is represented. c. Classification performances of the two models at threshold fixed to obtain 90 % sensitivity in relapse
detection. d. Coefficient and odds ratio of the model including BRCA1 expression parameters
Table 3 Performances metrics of the logistical regression models
Global model performances ROC Hosmer-Lemeshow
Variables pval −2LL R2 Nagelkerke AUC SE CI: Min CI : Max Chi2 ddl pval
Node, Tumor Size, CK5/6, miR-548c-5p 1.5E-4 15.570 .745 .96 .038 .883 1.000 5.08 7 .65
Node, Tumor Size, CK5/6, prot BRCA1, mRNA BRCA1,
BARD1 ligated BRCA1
.009 21.979 .590 .90 .065 .773 1.000 11.45 8 .18
Node, Tumor Size, CK5/6 .006 25.722 .484 .85 .072 .713 .996 2.96 7 .89
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(IHC) differences in BRCA1 protein expression were found
between cases with and without BRCA1 germline muta-
tions by Pérez-Vallés and colleagues [29]. To improve the
sensitivity and specificity of the BRCA1 detection compared
with IHC, we used proximity ligation assays with two
primary antibodies against the N- and C-terminus do-
mains of BRCA1. The second advantage of this tech-
nique was that it only allowed for the measurement of
the full-length proteins. BRCA1 must be ligated to its
interacting protein BARD1 to repair DNA. Some BRCA1
variants, such as splicing variants [29], can be expressed in
the tumor but can lose their interaction with their part-
ners. To obtain a reflection of BRCA1 function mainten-
ance in tumors, proximity ligation assay were performed
to visualize the portion of BRCA1 ligated to BARD1.
Although the three levels of BRCA1 tumoral expression
were correlated inside the same tumor, highly heterogenous
intra-tumoral expression was observed, hampering accurate
quantification. The lack of correlation between PFS and
BRCA1 expression was probably a consequence of this high
variability. We concluded that none of these three facets of
the BRCA1 tumoral expression could be used for clinical
decision purposes.
The TNBC cohort that we explored included six patients
with a known germline BRCA1 mutation. However, no
significant differences in BRCA1 expression at the levels
of mRNA, protein, or ligation to BARD1 were observed in
these cases, probably due to the small number of patients.
Interestingly, two of these six BRCA1 mutated patients
also presented a methylated form of the BRCA1 promoter,
although Lips et al. described these events as mutually ex-
clusive [30]. This combination of events could increase
the risk of breast cancer because these patients are also
the two youngest who developed breast cancer in our co-
hort of 69 patients, but this possibility will need to be con-
firmed on a larger cohort. The work of Ertuk and Cecener
also stated that miRNAs expression can be different in
BRCA1 mutated or normal TNBC tumors [31]. However,
we could not observe similar effect, probably due to the
small number of patients.
Statistical multivariate analysis demonstrated that miR-
548c-5p was an independent prognostic factor for breast
cancer. Patients with a good prognosis presented higher
intratumoral expression of this microRNA. Although im-
plicated in multiple biological processes including cancer,
no role for miR-548c-5p has ever been reported in the
breast cancer field. Mir-548 is a large, poorly conserved
primate-specific miRNA gene family. Sixty-nine human
mir-548 genes are located on almost all human chromo-
somes and its widespread distribution pattern and specific
sequence indicate its evolutionary origin from the MADE1
transposable element [32, 33]. There are more than 3500
putative mir-548 target genes, but none have been experi-
mentally demonstrated for miR-548c-5p.
The measurement of tumoral miR-548c-5p expression
levels in combination with three conventional breast
cancer prognostic factors (node invasion, tumor size and
cytokeratin 5/6 expression), allowed for the relapse predic-
tion of patients with an AUC= 0.96. A study in a larger co-
hort would be needed to confirm this observation, and to
determine whether quantification of this microRNA expres-
sion in the tumor could be used to steer patients with poor
predicted prognosis toward alternative chemotherapies.
We also showed that patients with poor predicted
prognoses calculated by this model presented higher
expression of miR-210, miR-503-5p and BRCA1 mRNA.
Indeed, high miR-210 expression has already been reported
by other teams to be correlated with relapse and short
survival [19, 34]. miR-503-5p was already emphasized in
our previous work: this microRNA is highly expressed in
endothelial cells and, can be secreted in exosomes and
transferred into breast cancer cell lines to inhibit tumor
growth by targeting CCND2 and CCND3 [35]. Moreover,
neoadjuvant chemotherapy for breast cancer leads to
increased plasma levels of miR-503, as also observed for
miR-34a, which could be implicated in the anti-tumor ef-
fects of chemotherapy in breast cancer patients [35, 36].
Concerning the higher expression of BRCA1 mRNA ob-
served in the poor-prognosis tumors, we could hypothesize
that patients expressing high levels of BRCA1 would
present a lower response to chemotherapy because TNBC
BRCA1 mutated patients are known to respond better to
chemotherapy [37].
MiR-484 was reported by Dvinge et al. as a good po-
tential housekeeping microRNA in breast cancer because
its expression was homogenous among samples in all
breast cancers subtypes [27]. However, Cox univariate
analysis showed that high miR-484 expression was as-
sociated with a bad prognosis in our TNBC cohort.
Volinia et al. also reported such an association [18]. In a
high-throughput study aiming at better defining miRNA-
mRNA interaction, BRCA1 was identified as interacting
with miR-484. However, we did not observed any inverse
correlation between those two parameters. Although,
miR-484 expression was strongly associated with two
other poor-prognosis miRNAs: miR-205 (Rho Spearman:
0.4, p-val :0.003) and miR-93 (Rho Spearman : 0.52, p-
val = 0.0001), the Diana MiRPath database did not present
any experimentally demonstrated common target gene of
the three miRNAs [38].
Conclusions
BRCA1 was expressed in a spatially heterogeneous man-
ner in TNBC, making very difficult any study correlating
its expression or activity with prognosis. However, this
study emphasized miR-548c-5p tumoral expression as a
new independent prognostic factor that could improve
the performance of relapse prediction models based on
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node invasion, tumor size and cytokeratin five and six
expression status.
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